xiliotx.com (XLO): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Xilio Therapeutics Inc (XLO)

Xilio Therapeutics, Inc. (XLO) is developing unique drugs that activate exclusively within neoplastic tissues, enabling an effective fight against resistant forms of diseases. This daily price chart of the asset with the 0.00 indicator complements the risk profile associated with dependence on Asian raw materials and the complexities of global trials. The absence of commercial products deprives the company of pricing power, making future profits dependent on the FDA verdict.

Xilio - XLO Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

Analytical breakdowns for Xilio Therapeutics, Inc.

Summary company analytics:Xilio Therapeutics Inc XLO
Product sample of Xilio Therapeutics

Developing innovative targeted cytokines on the GPS platform requires significant capital expenditures, making the analysis of Xilio Therapeutics, Inc. (XLO) valuation via EV/EBITDA trends critically important. This multiple compares the total enterprise value, including debt, against operating profit, allowing investors to objectively assess the real value of assets relative to cash flow generation capabilities while eliminating distortions from market expectations.

Analysis of competing companies

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara Therapeutics (TARA)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (aadibio.com)|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OSTX (OS Therapies Incorporated)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics Ltd|Company Value to EBITDA Artiva Biotherapeutics ARTV|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Therapeutics TPST|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple